Menu
Shedding Light on the Risks
& Benefits of Medications
Shedding Light on the Risks
& Benefits of Medications
Lotensin May Increase Risk of Low White Blood Cell Count
Lotensin May Increase Risk of Low White Blood Cell Count
June 30, 2016
0 Comments
republish
Lotensin May Increase Risk of Low White Blood Cell Count
on this page:
A common drug used to treat high blood pressure may elevate the risk in some patients of a condition in which a person’s white blood cell count is severely diminished, leaving them more susceptible to infection.
A recent case study discussed in the American Journal of Case Reports described a 61-year-old man who went to the emergency room with severe throat pain and difficulty swallowing that lasted over a week. He said he was being treated for hypertension, and was taking Norvasc (amlodipine) and Lotensin (benazepril) for it.
At the hospital, the patient was diagnosed with neutropenia, an abnormally low level of neutrophils, a type of white blood cell. He was admitted and given antibiotics for the pharyngitis he also had.
Given that the patient started Lotensin 2 months before symptoms started, and neutropenia is rarely seen with Norvasc, doctors suspected Lotensin to be the cause of his drug-induced agranulocytosis (DIAG). After he was taken off Lotensin, the patient achieved a quick recovery in white blood cell count. And after 3 weeks, the patient’s white blood cell count remained in the normal range.
Drugs to treat cancer and antibiotics are the most common causes of DIAG, and there have been prior instances of trial subjects taking Lotensin, which is considered an ACE inhibitor, a common class of high blood pressure drugs, who developed the condition.
“Because [ACE inhibitors] are commonly employed drugs, we report this case to increase awareness among prescribers about this rare but potentially lethal side effect of benazepril,” the authors concluded.
DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.
While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
on this page:
RECOMMENDED:
DONATE:
Help fund our fight for improved medication safety and transparency by supporting our independent journalism.
Give NowStay Informed. Sign up for our newsletters.
Independent, science-based journalism delivered directly to your inbox.
We seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.
WEBINARS
Learn about your medications and treatment options straight from independent experts.
WATCH
Article HTML
<!-- wp:paragraph -->
<p>A common drug used to treat high blood pressure may elevate the risk in some patients of a condition in which a person’s white blood cell count is severely diminished, leaving them more susceptible to infection.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>A recent case study discussed in the <a href="https://www.amjcaserep.com/abstract/index/idArt/898028" target="_blank" rel="noreferrer noopener">American Journal of Case Reports </a>described a 61-year-old man who went to the emergency room with severe throat pain and difficulty swallowing that lasted over a week. He said he was being treated for hypertension, and was taking Norvasc (amlodipine) and Lotensin (benazepril) for it.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>At the hospital, the patient was diagnosed with neutropenia, an abnormally low level of neutrophils, a type of white blood cell. He was admitted and given antibiotics for the pharyngitis he also had.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Given that the patient started Lotensin 2 months before symptoms started, and neutropenia is rarely seen with Norvasc, doctors suspected Lotensin to be the cause of his drug-induced agranulocytosis (DIAG). After he was taken off Lotensin, the patient achieved a quick recovery in white blood cell count. And after 3 weeks, the patient’s white blood cell count remained in the normal range.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Drugs to treat cancer and antibiotics are the most common causes of DIAG, and there have been prior instances of trial subjects taking Lotensin, which is considered an ACE inhibitor, a common class of high blood pressure drugs, who developed the condition.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>“Because [ACE inhibitors] are commonly employed drugs, we report this case to increase awareness among prescribers about this rare but potentially lethal side effect of benazepril,” the authors concluded.</p>
<!-- /wp:paragraph -->
<!-- wp:embed {"url":"https://youtu.be/BaqiXzrerJQ","type":"video","providerNameSlug":"youtube","responsive":true,"className":"wp-embed-aspect-16-9 wp-has-aspect-ratio"} -->
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
https://youtu.be/BaqiXzrerJQ
</div></figure>
<!-- /wp:embed -->